For our chat on 5/18/17, starting at 8 PM Eastern, 5 PM Pacific, we’ll cover several key trial results and the potential implications of them. While each has the potential to be practice changing, all three have the primary endpoint of progression-free survival (PFS) but, to our knowledge, don’t necessarily improve overall survival (OS). It is interesting that the differences between the settings and trial designs have led many lung cancer experts to favor adoption of some of these results but not necessarily others. But what do patients and caregivers think of… Read More
#LCSM Chat Topic 4/6: Who Needs Research Anyway: How Have You Been Impacted by Lung Cancer Research?
Our topic for the next #LCSM Chat on Thursday, April 6th at 5 PM Pacific/ 8 PM Eastern is “Who Needs Research Anyway: How Have You Been Impacted by Lung Cancer Research?” The moderator for this chat is Dr. David Tom Cooke (@DavidCookeMD) In its most recent budget outline, the Trump administration is looking to propose an 18% cut to the National Institute of Health’s (NIH; @NIH) $31.7 billion budget (#trumpbudget). In addition to this funding cut, the Trump administration proposes to 1) reorganize the current NIH institute structure and 2)… Read More
Our topic for the next #LCSM Chat on Thursday, March 23 at 5 PM Pacific (8 PM Eastern) will be “What Is a High-Value Cancer Drug?” With the price of new cancer drugs escalating, many are concerned about whether patients and the healthcare system can continue to access the most effective drugs. The 2016-2017 President’s Cancer Panel (PCP) topic is “Ensuring Patients’ Access to High-Value Cancer Drugs.” Andrew Schorr of Patient Power will be one of the patient advocates participating in the March 27, 2017 PCP meeting. This chat will help provide some inputs… Read More